A representative selection of early cancer diagnostic clinical trials focused on the diagnosis of pancreatic and liver cancers are examined within this section to gain an overall view of the past, present, and future state of clinical development. A selection of around 100 clinical trials from are examined against time, disease indication, and trial status. Early cancer diagnostic testing for pancreatic and liver cancers are just starting to see increased numbers in clinical development, with Figure showing a steady growth for pancreatic cancer starting in 2015 with a decrease in research in 2020 and then sharply increasing for the past few years. Liver cancer has seen oscillating growth with also a decrease in 2020 and then mirrors pancreatic cancer's sharp increase in activity within the past few years. Analysis of the above clinical trials by disease indication reveals that 59% of these trials are focused on the diagnosis of pancreatic cancer with 41% focused on the diagnosis of liver cancer (Figure ). Further analysis reveals the clinical trials statuses of early cancer diagnostic clinical trials focused on pancreatic and liver cancers. Most clinical trials for both indications are currently in recruiting status; gathering participants while getting ready to move into active status (Figure ). 60% of pancreatic cancer trials and 57% of liver cancer trials are in recruiting status. With less than 30% of trials being completed (Figure ), we can expect to see more active clinical trials soon. Currently only 10% of pancreatic cancer trials are in the active state with 18% active for liver cancer. Finally, representative clinical trials examining early cancer diagnostics focused on pancreatic and liver cancer are highlighted in Table and examined in further detail below to showcase the diversity and progress within the clinical development pipeline.